Immune-suppressive and immune-stimulating drugs and COVID-19 (search done: before 20 March 2020)
Citation: Russell B, Moss C, George G, et al. Associations between immune-suppressive and stimulating drugs and novel COVID-19: a systematic review of current evidence. Ecancermedicalscience 2020; 14: 1022
What is this? Immunosuppression is a risk factor for severe COVID-19 infection. Therefore, it is important to understand the associations between immunomodulatory medications and COVID-19 infection.
In this rapid review, the authors searched for research on the impact of immune-suppressing or immune-stimulating drugs on coronaviruses, including SARS-CoV-2 (the cause of COVID-19). They searched Ovid MEDLINE and although the date of the search is not reported, they submitted their manuscript to the journal on 20 March 2020. They included 89 studies covering 10 immunomodulatory medication groups, but not limited to COVID-19 patients.
What was found: At the time of this review, the included studies showed that low-dose prednisolone and tacrolimus may have beneficial impacts on COVID-19.
At the time of this review, the included studies showed that the associations with COVID-19 for mycophenolate mofetil, specific cytotoxic drugs, low-dose methotrexate for auto-immune disease, NSAIDs, JAK kinase inhibitors and anti-TNFα agents are uncertain.
At the time of this review, the included studies showed that interleukin-6 peak levels are associated with severity of pulmonary complication.
Disclaimer: This summary has been written by staff and volunteers of Evidence Aid in order to make the content of the original document accessible to decision makers who are searching for the available evidence on the coronavirus (COVID-19) but may not have the time, initially, to read the original report in full. This summary is not intended as a substitute for the medical advice of physicians, other health workers, professional associations, guideline developers, or national governments and international agencies. If readers of this summary think that the evidence that is presented within it is relevant to their decision-making they should refer to the content and details of the original article, and the advice and guidelines offered by other sources of expertise, before making decisions. Evidence Aid cannot be held responsible for any decisions made about the coronavirus (COVID-19) on the basis of this summary alone.
If you have found this summary helpful, please consider making a donation. If everyone who looked at our COVID-19 resources gave us just £2 per month, it would fund Evidence Aid’s life-saving work.